| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c683ef6c81ac4ffd81b81f7e5f8c1f6a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2005-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43dce6399f042f5634c7ddc98560bc3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d8c8835ddb7052ec4e672740d7755c0 |
| publicationDate |
2011-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20110018465-A |
| titleOfInvention |
Solid enteric oral dosage forms of bisphosphonates containing chelating agents |
| abstract |
Oral dosage forms of bisphosphonates comprising a bisphosphonate, a chelating agent, and a safe and effective amount of a pharmaceutical composition comprising a means for delaying the release of bisphosphonate and chelating agent from the lower gastrointestinal tract provide the pharmaceutical composition to the lower gastrointestinal tract of a mammalian subject. Deliver and allow the bisphosphonate to be absorbed pharmaceutically effectively with or without food or drink. The present invention substantially mitigates the interaction between bisphosphonates and food or beverages, which prevents the bisphosphonate active ingredient from being absorbed. The resulting oral dosage form can thus be taken with or without food. In addition, the present invention allows bisphosphonates and chelating agents to be delivered to the lower GI tract, substantially alleviating the upper GI stimulation associated with bisphosphonate therapy. These effects simplify previous complex treatment regimens and can increase patient compliance with bisphosphonate therapies. |
| priorityDate |
2004-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |